NH1,902.90

Narayana Hrudayalaya Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAPOLLOHOSPMAXHEALTHFORTISNEULANDLABNATCOPHARMLALPATHLABSAILIFECOHANCEMcap ₹38,888 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations1,305.21,203.61,279.41,341.01,400.01,366.71,475.41,507.31,643.82,151.22,593.82,683.6
Other Income18.417.923.923.523.618.426.823.824.023.229.235.5
Total Income1,323.61,221.51,303.31,364.41,423.61,385.01,502.31,531.11,667.82,174.42,623.02,719.1
Expenses
+ Purchases of Stock-in-Trade284.0259.2293.9281.9316.6269.7305.4305.4323.0407.4524.6520.3
+ Changes in Inventories0.5-14.9-20.46.3-16.46.6-0.10.4-0.7-26.0-18.0-6.0
+ Employee Benefit Expense255.3254.2249.4276.4282.1277.3275.4295.5299.1459.5748.9724.8
+ Finance Costs22.925.128.034.035.136.640.745.242.365.091.386.8
+ Depreciation & Amortisation55.363.264.861.765.170.082.584.387.5122.3153.8156.1
+ Other Expenses457.4426.2462.0472.5509.3506.1537.0569.0620.0943.0828.3974.8
Total Expenses1,075.31,012.91,077.71,132.81,191.81,166.21,240.91,299.81,371.01,971.22,328.92,456.8
EBITDA308.1278.9294.6303.9308.4307.0357.7337.0402.5367.2510.0469.7
EBIT252.8215.8229.8242.2243.3237.0275.2252.6315.0245.0356.2313.6
Profit
PBT before Exceptional Items248.4208.6225.6231.7231.8218.8261.4231.3296.8203.2294.2262.3
+ Exceptional Items0.00.00.00.00.00.0-8.40.00.0-50.9-0.00.0
Pretax Income248.4208.6225.6231.7231.8218.8253.0231.3296.8152.2294.1262.3
+ Current Tax29.526.151.229.929.128.842.034.236.230.176.155.7
+ Deferred Tax-7.8-5.7-16.40.33.9-3.114.80.61.0-7.8-12.0-2.6
Tax Expense21.720.534.830.233.025.856.834.837.222.364.153.1
Net Income226.7188.1190.8201.5198.8193.1197.3196.7258.5126.8224.0207.3
+ Net Income — Continuing Ops226.7188.1190.8201.5198.8193.1196.2196.1258.3128.1228.0207.3
+ Net Income — Discontinued Ops0.00.00.00.00.00.01.00.70.2-1.3-4.00.0
+ Other Comprehensive Income14.6-1.14.4-2.15.336.4-5.90.569.430.396.5-13.2
Total Comprehensive Income241.3187.0195.2199.4204.1229.4191.4197.2327.9157.1320.5194.0
Net Income to Common226.6188.0190.7201.4198.6192.9197.2196.7258.4126.7223.9207.2
Minority Interest0.10.10.10.10.20.10.10.10.10.10.10.1
Per Share
Basic EPS11.169.269.399.929.789.509.719.6812.726.2411.0210.20
Diluted EPS11.169.269.399.929.789.509.719.6812.726.2411.0210.20
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax0.00.00.00.00.00.01.80.70.2-1.3-3.30.0
+ Tax — Discontinued Operations0.00.00.00.00.00.00.70.10.00.00.70.0
Other Comprehensive Income — detail
+ Other Comprehensive Income-5.90.569.430.396.5-13.2
+ Items NOT to be Reclassified to P&L0.1-0.8-0.5-4.1-0.7-0.5-0.00.9-1.9-1.30.8-6.5
+ Tax on Items NOT to be Reclassified-0.4-0.20.1-0.20.6-1.2
+ Tax on Items NOT to be Reclassified — alt tag0.0-0.2-0.2-0.9-0.2-0.1
+ Items to be Reclassified to P&L14.6-0.54.71.15.836.8-6.3-0.671.431.396.4-7.9
+ Tax on Items to be Reclassified0.00.00.0-0.10.00.0
+ Tax on Items to be Reclassified — alt tag0.10.0-0.0-0.0-0.00.0
+ Net Movement — Regulatory Deferral Balances0.00.00.00.00.00.00.0-0.4-1.3-1.9-2.0-1.9
Comprehensive Income — Owners of Parent241.2186.94.4199.3204.0229.3-5.9197.1327.8157.0320.5194.0
Comprehensive Income — Non-controlling Interests0.10.1-0.00.10.20.1-0.00.10.10.10.10.1
Per Share — as-filed variants
Basic EPS — Continuing Operations11.169.269.399.929.789.509.669.6512.716.3011.2210.20
Diluted EPS — Continuing Operations11.169.269.399.929.789.509.669.6512.716.3011.2210.20
Basic EPS — Discontinued Operations0.000.000.000.000.000.000.050.030.01-0.06-0.200.00
Diluted EPS — Discontinued Operations0.000.000.000.000.000.000.050.030.01-0.06-0.200.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,020.8959.41,005.91,052.71,099.81,090.31,170.11,201.51,321.61,769.72,087.22,169.4
Gross Margin %78.2079.7178.6278.5178.5679.7879.3179.7180.4082.2780.4780.84
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)248.4208.6225.6231.7231.8218.8261.4231.3296.8203.2294.2262.3
− Exceptional Items (reconciliation)0.00.00.00.00.00.0-8.40.00.0-50.9-0.00.0
Net Income Adj (tax-effected)226.7188.1190.8201.5198.8193.1203.8196.7258.5170.3224.0207.3
EPS Adj11.169.269.399.929.789.5010.039.6812.728.3811.0210.20
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Filed Debt Equity0.010.010.010.010.010.010.010.010.010.01
Filed Dscr0.030.030.030.030.030.020.030.020.020.02
Filed Iscr0.090.080.080.070.070.060.080.030.040.04
Paid Up Equity Capital204.4204.4204.4204.4204.4204.4204.4204.4204.4204.4204.4204.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.